Genprex (NASDAQ:GNPX) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS
Genprex (NASDAQ:GNPX) released its quarterly earnings data on Tuesday. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.03), Bloomberg Earnings reports.
Shares of NASDAQ GNPX traded down $0.06 during trading hours on Wednesday, reaching $0.86. The stock had a trading volume of 6,772 shares, compared to its average volume of 40,343. The stock has a market capitalization of $15.56 million, a price-to-earnings ratio of -0.96 and a beta of 1.49. Genprex has a fifty-two week low of $0.64 and a fifty-two week high of $2.98. The business’s 50-day simple moving average is $1.07.
GNPX has been the subject of several analyst reports. Noble Financial initiated coverage on Genprex in a research report on Monday, April 29th. They set an “outperform” rating and a $5.00 price objective for the company. ValuEngine raised Genprex from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research raised Genprex from a “sell” rating to a “hold” rating in a research report on Tuesday, June 18th.
Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.
Recommended Story: Insider Trading
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.